A Phase IIIb, Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory, Single-dose Crossover Study With Indacaterol 75 microgram Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase III
Latest Information Update: 09 May 2013
At a glance
- Drugs Indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 31 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2012 New trial record